UnknownNot applicableNCT02530619
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Studying Acute megakaryoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northwestern University
- Principal Investigator
- Brady Stein, MDNorthwestern University
- Intervention
- Alisertib(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2022
Study locations (3)
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Mayo Clinic, Rochester, Minnesota, United States
Collaborators
The Leukemia and Lymphoma Society · Millennium Pharmaceuticals, Inc. · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02530619 on ClinicalTrials.gov